CVD Prevention Models in Sub-Saharan Africa: Insights and Gaps

By João L. Carapinha

February 24, 2025

How can decision analytic models improve cardiovascular disease prevention in Sub-Saharan Africa? A recent article on the application of decision analytic modelling to cardiovascular disease prevention in Sub-Saharan Africa explored the use of decision analytic models (DAMs) for evaluating interventions aimed at cardiovascular disease (CVD) prevention in Sub-Saharan Africa (SSA). It highlights that CVDs represent a significant burden in SSA, with an upward trend observed over the last three decades.

The review encompasses 27 studies from eight SSA countries, concentrating on model-based economic evaluations of CVD prevention models. Most studies focused on primary CVD prevention, with pharmacological interventions, particularly antihypertensives and statins, being most common. Markov models were frequently utilized, and the Framingham risk equations were applied to estimate 10-year CVD risk.

Notes from the Study

Most studies centered on primary CVD prevention, with pharmacological interventions being the predominant focus. Markov models and microsimulation models were the most utilized, with Markov models appearing in 13 studies and microsimulation models in seven. Only seven studies integrated equity dimensions, primarily through subgroup analysis, focusing on gender, socioeconomic, and regional inequalities.

Significant data gaps emerged, especially concerning intervention effectiveness and CVD risk equations, highlighting a lack of local data for generating 10-year CVD risk assessments. The mean quality score of the papers was 68.9%, although inconsistencies and data limitations were apparent, with only three studies undertaking model validation.

Health Economic Implications

The findings emphasize the necessity for enhanced health economic evaluations that factor in equity dimensions to guide policy decisions on CVD prevention in SSA. Longitudinal studies are essential for refining CVD risk prediction and local health outcome valuation studies. The review indicated that policymakers must prioritize cost-effective and equitable interventions to strive for universal health coverage (UHC). Strengthening primary healthcare systems is vital for scaling up effective CVD prevention models.

Future Studies

Future studies should aim to address primordial prevention and lifestyle interventions, which are currently undervalued. There is also an urgent need for improved model validation, calibration, and stakeholder engagement in the modeling process.

The review highlighted the importance of adhering to best practices in developing DAMs, such as utilizing local data, ensuring model validation, and maintaining transparency in the modeling process. The absence of local data for generating 10-year CVD risk equations and utility values for QALYs reveals significant research gaps. Incorporating equity considerations in economic evaluations is crucial, particularly through newer methods like extended and distributional cost-effectiveness analyses. There is a call for increased emphasis on longitudinal studies and local health valuation studies to enhance the accuracy and relevance of CVD prevention models in SSA.

Reference url

Recent Posts

prior authorization elimination
   

Prior Authorization Elimination: Is Optum Rx moving towards Access Efficiency?

🚀 Are prior authorizations holding back patient access to crucial medications?

Optum Rx is set to eliminate prior authorizations for about 80 drugs starting May 1, 2025, streamlining access to treatments for chronic conditions like cystic fibrosis and asthma. This significant move is aimed at reducing unnecessary administrative burdens, ultimately enhancing patient care.

Curious about the implications for the healthcare system and potential cost savings? Dive into the full article for an in-depth look!

#SyenzaNews #healthcare #HealthEconomics

South Africa cannabis regulations
     

South Africa Cannabis Regulations: Government Withdraws Ban for New Framework Development

🌿 Curious about the future of cannabis in South Africa?

Recent developments have seen the government retract its ban on hemp and cannabis food products, signaling a major shift towards a more responsible regulatory framework. With a focus on stakeholder consultation, this move aims to foster industry growth while prioritizing public health.

Explore how these changes are set to reshape the landscape of the cannabis industry in South Africa and beyond!

#SyenzaNews #HealthEconomics #MarketAccess

lumped parameter model
      

Advancing Heart Transplantation: The Role of the Lumped Parameter Model

🫀 How can a new model improve heart transplantation?

A recent study introduces a **lumped parameter model (LPM)** designed to enhance the evaluation of donor heart function during ex vivo perfusion, aiming to boost donor heart utilization and reduce primary graft dysfunction rates. This innovative approach holds promise for improving clinical decision-making and outcomes in heart transplantation.

Dive into the article for insightful details on how LPMs could reshape the future of cardiac care!

#SyenzaNews #HealthcareInnovation #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.